Mariann Harangi
Mariann Harangi
University of Debrecen Faculty of Medicine
Email verificata su
Citata da
Citata da
The impact of obesity on the cardiovascular system
I Csige, D Ujvárosy, Z Szabó, I Lőrincz, G Paragh, M Harangi, S Somodi
Journal of diabetes research 2018, 2018
Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
AJ Vallejo-Vaz, CAT Stevens, ARM Lyons, KI Dharmayat, T Freiberger, ...
The Lancet 398 (10312), 1713-1725, 2021
Hypertension in thyroid disorders
E Berta, I Lengyel, S Halmi, M Zrínyi, A Erdei, M Harangi, D Páll, EV Nagy, ...
Frontiers in endocrinology 10, 482, 2019
Serum paraoxonase activity changes in uremic and kidney-transplanted patients
G Paragh, L Asztalos, I Seres, Z Balogh, L Löcsey, I Kárpáti, J Mátyus, ...
Nephron 83 (2), 126-131, 1999
Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage
M Harangi, I Seres, Z Varga, G Emri, Z Szilvássy, G Paragh, É Remenyik
European Journal of Clinical Pharmacology 60, 685-691, 2004
Association of chemerin with oxidative stress, inflammation and classical adipokines in non‐diabetic obese patients
P Fülöp, I Seres, H Lőrincz, M Harangi, S Somodi, G Paragh
Journal of cellular and molecular medicine 18 (7), 1313-1320, 2014
Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates?
Z Balogh, I Seres, M Harangi, P Kovacs, GY Kakuk, GY Paragh
Diabetes and Metabolism 27 (5; PART 1), 604-610, 2001
Contribution of animal models to the understanding of the metabolic syndrome: a systematic overview
O Varga, M Harangi, IAS Olsson, AK Hansen
Obesity Reviews 11 (11), 792-807, 2010
The human paraoxonase‐1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters
HZ Mirdamadi, F Sztanek, Z Derdak, I Seres, M Harangi, G Paragh
British journal of clinical pharmacology 66 (3), 366-374, 2008
The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease
G Paragh, I Seres, M Harangi, Z Balogh, L Illyes, J Boda, Z Szilvássy, ...
Diabetes & metabolism 29 (6), 613-618, 2003
Human paraoxonase-1 activity in childhood obesity and its relation to leptin and adiponectin levels
P Koncsos, I Seres, M Harangi, I Illyés, L Józsa, F Gönczi, L Bajnok, ...
Pediatric research 67 (3), 309-313, 2010
Determination of DNA damage induced by oxidative stress in hyperlipidemic patients
M Harangi, É Remenyik, I Seres, Z Varga, E Katona, G Paragh
Mutation Research/Genetic Toxicology and Environmental Mutagenesis 513 (1-2 …, 2002
Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia
G Paragh, D Tör’’ocsik, I Seres, M Harangi, L Illyés, Z Balogh, P Kovacs
Current medical research and opinion 20 (8), 1321-1327, 2004
High-density lipopoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus
K Gaál, T Tarr, H Lőrincz, V Borbás, I Seres, M Harangi, P Fülöp, ...
Lipids in health and disease 15, 1-8, 2016
Orlistat increases serum paraoxonase activity in obese patients
M Audikovszky, G Pados, I Seres, M Harangi, P Fülöp, E Katona, L Illyés, ...
Nutrition, metabolism and cardiovascular diseases 17 (4), 268-273, 2007
Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity
M Harangi, HZ Mirdamadi, I Seres, F Sztanek, M Molnár, A Kassai, ...
Translational Research 153 (4), 190-198, 2009
Decreased paraoxonase 1 (PON1) lactonase activity in hemodialyzed and renal transplanted patients. A novel cardiovascular biomarker in end-stage renal disease
F Sztanek, I Seres, M Harangi, L Lőcsey, J Padra, GJR Paragh, L Asztalos, ...
Nephrology Dialysis Transplantation 27 (7), 2866-2872, 2012
The molecular and clinical rationale of extracorporeal photochemotherapy in autoimmune diseases, malignancies and transplantation
P Szodoray, G Papp, B Nakken, M Harangi, M Zeher
Autoimmunity Reviews 9 (6), 459-464, 2010
Alteration of PON1 activity in adult and childhood obesity and its relation to adipokine levels
I Seres, L Bajnok, M Harangi, F Sztanek, P Koncsos, G Paragh
Paraoxonases in Inflammation, Infection, and Toxicology, 129-142, 2010
Strong correlations between circulating chemerin levels and lipoprotein subfractions in nondiabetic obese and nonobese subjects
H Lőrincz, M Katkó, M Harangi, S Somodi, K Gaál, P Fülöp, G Paragh, ...
Clinical endocrinology 81 (3), 370-377, 2014
Il sistema al momento non puň eseguire l'operazione. Riprova piů tardi.
Articoli 1–20